# Andrew O'Brien

> Andrew O'Brien is a pre-seed investor backing Biopharma and Health Care. See 1 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Total investments: 1
- Last investment: Oct 2024
- Lead investor: 0%
- Last updated: Aug 2026

Andrew O'Brien is a pre-seed investor focused on Biopharma and Health Care.

## Contacts

5 contacts available for Andrew O'Brien: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/andrew-o-brien-6a8f?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 100% |
| Health Care | 1 | 100% |
| Dietary Supplements | 1 | 100% |
| Artificial Intelligence | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| vivaLAB | vivaLAB is an AI driven, digital health company delivering on the significant but unrealised promise of personalised health. The company has built a unique data platform called vivaSOPHIA capturing both consumer real world data (such as lifestyle, nutrition, sleep, exercise, medication & status of the onset of chronic diseases) with muti-omicsdata (>8,000 biomarkers) from gut microbiome (metagenomics) & metabolic health (metabolomics) testing. vivaLAB collects omics data every 6 months, with the lifestyle data complemented by wearables data collected on a daily basis. Using this unique dataset, vivaLAB is developing multiple AI products:1. vivaDIETETICA: Digitised “Dietitian” to improve consumer health and wellness 2. vivaBIODIVE: Biomarker identification position to develop next gen health products incl: probio-pharmaceuticals, diagnostics, digital medical devices & therapeutics 3. vivaEARLYGUARD: Patient clustering analytics & development of early disease detection models 4. vivaTREND: Identify wellness trends, nutraceutical and probiotic product development & establish a health “snapshot” of populations & geographic regionsThe 1st product, vivaDIETETICA, launched in Australia in June 2023 as an MVP of up to 500 consumers is a disruptive DTC offer to the large and growing Vitamins & Dietary Supplement market, with a $3.1b TAM in Aust & $163b globally in 2022, growing at 9% CAGR to 2030. Delivering a personalised wellness plan, this highly differentiated offer empowers consumers with data that is refreshed every 6 months. So as a consumer ages or lifestyle changes, so does vivaDIETETICA's recommendations maintaining consumer health & wellnessThis AI product development program represents a large global TAM being addressed either in-house in selected areas, or in partnership. The experienced founding team have built a comprehensive tech stack & compelling consumer offer ready for rapid scaling and international launch in the coming year. | $1.1M | Pre-Seed | Oct 01, 2024 | https://x.com/vivalab_health |

1 of 1 investments shown.

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Artesian VC](https://shizune.co/investors/profile/artesian-capital-management) — VC Fund
- [Blackbird Ventures](https://shizune.co/investors/profile/blackbird-ventures-australia) — VC Fund

## Featured in investor lists
- [Food and Beverage Angel Investors in Australia](https://shizune.co/investors/food-and-beverage-angel-investors-australia)
- [Biotechnology Angel Investors in Australia](https://shizune.co/investors/biotechnology-angel-investors-australia)
- [Biotechnology Angel Investors in Oceania](https://shizune.co/investors/biotechnology-angel-investors-oceania)
- [Biotech Angel Investors in Australia](https://shizune.co/investors/biotech-angel-investors-australia)

## FAQ

### What does Andrew O'Brien invest in?

Andrew O'Brien invests primarily in Biopharma, Health Care and Dietary Supplements startups, most often at Pre-Seed stage. Most of the 1 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Andrew O'Brien?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Andrew O'Brien last invest?

The most recent investment recorded for Andrew O'Brien closed in Oct 2024. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co